-
FDA Approves Xermelo
drugs.com
March 01, 2017
FDA Approves Xermelo (telotristat ethyl) as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors
-
FDA Approves Qtern
drugs.com
March 01, 2017
FDA Approves Once-Daily Qtern (dapagliflozin and saxagliptin) Tablets for Adults with Type-2 Diabetes
-
US FDA awards orphan drug designation to Minoryx’s MIN-102 compound
pharmaceutical-technology
February 27, 2017
The US Food and Drug Administration (FDA) has granted orphan drug designation to Minoryx Therapeutics’ lead compound MIN-102.
-
FDA Clears Test to Help Manage Antibiotic Treatment for Lower Respiratory Tract Infections and Sepsi
americanpharmaceuticalreview
February 27, 2017
The U.S. Food and Drug Administration has cleared the expanded use of the Vidas Brahms PCT Assay to help health care providers determine if antibiotic treatment should be started or stopped in patients with lower respiratory tract infections, such as comm
-
US FDA accepts regulatory submission for Pfizer’s inotuzumab ozogamicin
pharmaceutical-technology
February 24, 2017
US-based pharmaceutical company Pfizer’s biologics licence application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted priority review by the US Food and Drug Administration (FDA).
-
US FDA grants fast-track designation to Cell Medica's CMD-003
pharmaceutical-technology
February 23, 2017
The US Food and Drug Administration (FDA) has granted fast-track designation to UK-based cellular immunotherapy firm Cell Medica's oncology product CMD-003 (baltaleucel-T).
-
FDA rejects Amphastar's filing for intranasal naloxone as opioid overdose treatment
firstwordpharma
February 22, 2017
Amphastar Pharmaceuticals announced Tuesday that the FDA issued a complete response letter regarding the company's filing seeking approval of intranasal naloxone for the emergency treatment of known or suspected opioid overdose.
-
FDA Approves Perrigo’s Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution
americanpharmaceuticalreview
February 22, 2017
Perrigo Company has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL.
-
World's first health monitoring system in a smartphone ready for FDA approval
biospectrumasia
February 21, 2017
Blood pressure and other vital signs system accuracy already proven in trials
-
FDA to review Mylan and Biocon’s biosimilar application
europeanpharmaceuticalreview
February 20, 2017
The US Food and Drug Administration (FDA) has accepted Mylan and Biocon‘s biologics license application for MYL-1401H, a proposed biosimilar to Neulasta (pegfilgrastim).